Free Public Seminar
BCG: Into the Next Century
The BCG vaccine was developed more than 100 years ago to combat tuberculosis (TB) and is the most commonly administered vaccine in human history.
Recent breakthroughs in research suggest that BCG may be an unexpected tool for combating more than just TB. This century-old vaccine shows promise in applications against type 1 diabetes, newborn sepsis, infant allergies, asthma, and more.
On May 6th, join leading experts as they share insights from their research and examine how BCG could be deployed optimally in the years to come.
Details
DATE: Tuesday, May 6th, 2025
TIME: 9 a.m. – 4:30 p.m.
LOCATION:
Sir Charles Tupper Medical Building, Theatre D
Dalhousie University, Halifax, NS
COST: Free
Registration is not required for this event.
Speakers:
Dr. Marcel Behr, McGill University
Intro to BCG & TB; Evidence For/Against Adaptive vs Innate Immune Mediated Protection
Dr. Maziar Divangahi, McGill University
BCG Innate Immunity and Early Clearance
Dr. Mathy Jeyanathan, McMaster University
BCG Innate Immunity and Gut-lung Axis
Dr. Denise Faustman, Harvard University
BCG and Protection from Diabetes Mellitus Type 1
Dr. Nelly Amenyogbe, Dalhousie University
BCG and Protection from Neonatal sepsis
Dr. Eva Kaufmann, Queens University
BCG and Protection from Asthma
Dr. Marie-Claude Rousseau, Université Laval
Canadian Context for ‘Epidemiology’ of BCG
